1. Medtech Insight
  2. >>Digital Technologies
  3. >>AI

HIMSS 2022: GE Introduces Edison Platform To Integrate Clinical Data From Multiple Sources

 
• By Reed Miller

The Edison Digital Health Platform is a “vendor-agnostic” platform with an integrated AI engine that will allow health care systems to aggregate data from connect devices and other sources.

Cyber heart pulse futuristic 3D rendering illustration. Concept of romance, love, health, medicine and advanced cybernetic technology. Abstract digita - Image ID: 2AAFJ6F
• Source: Alamy

GE Healthcare is currently recruiting health care systems to help it evaluate its new Edison Digital Health Platform, the company announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando on 15 March.

Edison is designed to seamlessly aggregate data from multiple devices or other sources, including devices and software not made by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

PathAI Expands AISight Dx Label With PCCP-Guided Addition Of Roche Scanners

 
• By Natasha Barrow

Roche’s scanners have been integrated with PathAI’s AISight Dx system. The system’s FDA-cleared PCCP allows new components to be validated and integrated without additional FDA clearance. Eric Walk, chief medical officer, hints at future biopharma companion diagnostic collaborations.

Fairtility’s FDA-Cleared CHLOE Brings AI To Embryo Selection

 
• By Elizabeth Orr

Israeli device firm Fairtility recently obtained US FDA clearance for the CHLOE platform, which uses AI to make embryo assessments performed as part of in vitro fertilization more transparent, efficient and reliable.

Salient Bio Raises £2.35M For March 2026 Rollout Of At-Home IBD Microbiome Test

 
• By Natasha Barrow

Salient's inflammatory bowel disease test, built on the start-up’s Signal platform, is planned to launch in March 2026. The company leverages rich data from existing wellness tests to develop signatures, focusing on conditions that are often misdiagnosed and disproportionately affect women.

FDA’s New AI Councils Focus On ‘Responsible’ Adoption And Regulation

 
• By Sarah Karlin-Smith

The agency is creating two new AI councils to facilitate its role in responsible AI adoption and regulation.

More from Digital Technologies

Tariffs In Focus: Projections From 4 Medtech Giants (Q1 Vs Q2)

 
• By Marion Webb, Shubham Singh, and Nancy Pham

Roche Diagnostics, Intuitive Surgical, Abbott and Edwards Lifesciences all acknowledge tariff headwinds, but stress preparedness, resilience and mitigation. Below is look at how management framed the impact in Q1 vs Q2 earnings calls.

Oura Gets Competitors Banned From US Market, But Faces Ultrahuman Countersuit

 
• By Elizabeth Orr

The US International Trade Commission has banned smart rings from Ultrahuman and RingConn after Oura Health's patent infringement case. Ultrahuman countersued, claiming Oura infringes its intellectual property. Sales and marketing of the affected rings will cease on October 22.

Study Finds Public Companies Behind Most Recalled AI Devices

 
• By Elizabeth Orr

A Johns Hopkins University study found publicly traded companies are responsible for 90% of recalled AI-powered medical devices. The study attributes this link to lower clinical validation, especially among smaller companies, and advocates for increased clinical trials to enhance device safety.